Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Gujarat Themis to acquire MicroBiopharm Japan

PRIVATEAug 22, 2026•about 4 hours ago

Acquiring Company

Gujarat Themis Biosyn

Acquired Company

MicroBiopharm Japan Ltd

MumbaiJapanManufacturingBiotechnologyHealth CarePharmaceuticalManufacturingBiotechnology

Description

Gujarat Themis Biosyn is set to acquire MicroBiopharm Japan Co., Ltd. for approximately JPY 21.5 billion. This acquisition is aimed at broadening GTBL's portfolio in oncology and immunosuppressants. The deal is expected to close in Q2FY27 pending regulatory approvals. This move represents a significant step in Gujarat Themis's strategy for inorganic growth and global expansion.

Company Information

Company

Gujarat Themis Biosyn

Location

Mumbai, Maharashtra, India

About

Gujarat Themis Biosyn is a leading Indian company specializing in the development and manufacturing of pharmaceuticals and specialty chemicals. With decades of experience in the industry, the company focuses on innovative solutions and high-quality products. It is publicly traded and actively engages in strategic acquisitions to expand its business portfolio.

Don't miss Gujarat Themis Biosyn's next move

Get an email the moment Gujarat Themis Biosyn makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Gujarat Themis Biosyn's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired MicroBiopharm Japan Ltd?

MicroBiopharm Japan Ltd was acquired by Gujarat Themis Biosyn, based in Mumbai. The deal was reported on August 22, 2026. Gujarat Themis Biosyn is a leading Indian company specializing in the development and manufacturing of pharmaceuticals and specialty chemicals. Gujarat Themis Biosyn is privately held and operates in Manufacturing.

When did Gujarat Themis Biosyn acquire MicroBiopharm Japan Ltd?

Gujarat Themis Biosyn's acquisition of MicroBiopharm Japan Ltd was reported on August 22, 2026. Gujarat Themis Biosyn is set to acquire MicroBiopharm Japan Co., Ltd. for approximately JPY 21.5 billion. This acquisition is aimed at broadening GTBL's portfolio in oncology and immunosuppressants. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does MicroBiopharm Japan Ltd do?

MicroBiopharm Japan Co., Ltd. (MBJ) is a well-established Japanese company with over sixty years of experience in fermentation and microbial-based R&D. It is privately held, operating in Manufacturing, and is based in Japan.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.